Weight-Loss Drugs
CagriSema: how to read the combination-treatment evidence
The cagrilintide–semaglutide combination has Phase 3 evidence. Its analysis, study population, and regulatory status need separate labels.
Why daily body weight fluctuates
One weigh-in measures total body mass. A useful trend needs context, consistent conditions, and room for normal variation.